文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

骨髓纤维化移植围手术期JAK抑制剂治疗的临床与免疫效应

Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis.
PubMed 文献 · Am J Hematol · 2024-11-16

该研究分析骨髓纤维化首次移植患者不同移植平台,比较围移植期持续JAK抑制(PERI组33例)、移植前JAK抑制(PRE组38例)和从未接受JAK抑制(NON组38例)的免疫特征与结局。PERI组早期B细胞恢复更高,晚期γδT细胞和NK细胞恢复增加,中性粒细胞和血小板植入率均为100%,无血液毒性或感染增加。PERI组100天急性GvHD II-IV累积发生率15%,PRE组29%,NON组34%;1年复发累积发生率PERI组9%,PRE组16%,NON组18%。

要点

  • 围移植期持续JAK抑制组中性粒细胞和血小板植入率均为100%,无血液毒性或感染增加。
  • PERI组100天急性GvHD II-IV累积发生率为15%,PRE组29%,NON组34%。
  • PERI组1年复发累积发生率为9%,PRE组16%,NON组18%。

核心结论

  • 围移植期JAK抑制可行,植入和急性GvHD发生率令人鼓舞,但值得进一步研究。

研究设计与样本

  • 分析骨髓纤维化首次移植患者的不同移植平台,比较PERI组33例(从预处理开始持续JAK抑制至稳定植入)、PRE组38例(移植前JAK抑制至预处理开始)和NON组38例(从未接受JAK抑制)的免疫特征与结局。

主要发现

  • PERI组早期B细胞恢复显著更高,晚期γδT细胞和NK细胞恢复显著增加。
  • PERI组中性粒细胞和血小板植入率均为100%,围移植期JAK抑制后无血液毒性效应或感染率增加。
  • 移植后100天急性GvHD II-IV累积发生率:PERI组15% vs PRE组29% vs NON组34%。
  • 移植后1年复发累积发生率:PERI组9% vs PRE组16% vs NON组18%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the introduction of JAK inhibitors, allogeneic hematopoietic cell transplant remains the only potentially curative treatment for patients with myelofibrosis but has considerable treatment-related complications. Whether the incorporation of JAK inhibition into the transplant algorithm leads to improved outcomes is still unclear. Here, we analyzed different transplant platforms in myelofibrosis patients undergoing a first transplant, comparing immune profiles and outcomes of (1) 33 patients continuing JAK inhibition at start of conditioning until stable engraftment (PERI-group), (2) 38 patients receiving JAK inhibition prior to transplant until start of conditioning (PRE-group), and (3) 38 patients that had never received JAK inhibition (NON-group). Patients in the PERI-group showed significantly higher early B-cell recovery as well as significantly increased late recovery of gamma-delta T cells and NK cells. We observed excellent neutrophil and platelet engraftment (100% for both) in the PERI-group and no hematotoxic effects or increased rates of infections following peri-transplant JAK inhibition. Cumulative incidence of acute graft-versus-host disease (GvHD) grade II-IV at day 100 after transplant was 15% in the PERI-group versus 29% in the PRE-group versus 34% in the NON-group. Cumulative incidence of relapse at 1 year after transplant was 9% in the PERI-group compared with 16% in the PRE-group and 18% in the NON-group. In conclusion, peri-transplant JAK inhibition was feasible with promising engraftment and acute GvHD rates, though deserves further investigation.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Rathje K, Gagelmann N, Badbaran A, et al. Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis. Am J Hematol. 2024. PMID: 39548811. doi:10.1002/ajh.27529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。